Skip to main content

Table 3 Use of antiviral prophylaxis and HBV infection management in DLBCL patients receiving R-chemo

From: Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

Management of HBV infection HBsAg-pos (n = 24) HBsAg-neg/HBcAb-pos (n = 69) HBsAg/HBcAb double-neg (n = 149) Unknown (n = 37)
HBsAb positivity, n (%) 3 (12.5) 53 (76.8) 58 (38.9) 1 (2.7)
Antiviral prophylaxis
Received antiviral prophylaxis, n (%) 17 (70.8) 7 (10.1) 0 (0.0) 1 (2.7)
Median number of cycles administered when prophylaxis was initiated (range)
Time started with prophylaxis relative to R-Chemo (range) 1 (1, 1) 1 (1, 1) 1 (1, 1)
Stopped prophylaxis by 120 d after last R dose, n (%)
Antiviral treatment duration, day (range) −1 (–20, 2)1 0 (−1, 0) −4 (−4, −4)
4 (16.7) 3 (4.3) 0
9 (4–12)1 6 (1–185)
Monitored for serologic markers,2 n (%) 14 (58.3) 36 (52.2) 68 (45.6) 2 (5.4)
Median interval, day (range) 53.7 (25–205) 37.0 (18–291) 35.3 (21–315) 24.0 (21–27)
First check after R-chemo, day (range) 26.0 (1–34) 23.0 (1–61) 19.0 (1–90) 20.0 (20–20)
Monitored for HBV DNA,3 n (%) 18 (75.0) 21 (30.4) 15 (10.1) 7 (18.9)
Median interval, d (range) 34.9 (22–267) 35.6 (21–168) 40.8 (21–136) 40.0 (22–143)
First check after R-chemo, d (range) 21.5 (1–49) 24.0 (1–61) 4.0 (1–25) 21.0 (20–122)
Monitored for liver function,4 n (%) 23 (95.8) 65 (94.2) 144 (96.6) 37 (100)
Median interval, d (range) 29.9 (20–48) 29.2 (21-51) 28.4 (4–82) 29.0 (15–61)
First check after R-chemo, d (range) 26.5 (20–9) 34.0 (8–114) 25.0 (1–117) 22.0 (1–120)
  1. 1Information on use of antiviral prophylaxis was missing for one subject and was thus not included in the analysis
  2. 2HBsAg and HBeAg levels were monitored at least twice in the study, including at baseline
  3. 3HBV DNA was monitored at least twice, including at baseline
  4. 4ALT levels were monitored at least twice, including at baseline
  5. chemo, chemotherapy; DLBCL, diffuse large B-cell lymphoma; HBcAb, hepatitis B core antibody; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; neg, negative; pos, positive; R, rituximab